CMRX
CMRX Real Time Price USDRecent trades of CMRX by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by CMRX's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
-
$20,000 Jan 19, 2023 Issue: None
-
$50,000 Oct 17, 2022 Issue: Health Issues
-
$50,000 Jul 19, 2022 Issue: Health Issues
-
$50,000 Apr 18, 2022 Issue: Health Issues
-
$50,000 Jan 14, 2022 Issue: Health Issues
-
$50,000 Oct 18, 2021 Issue: Health Issues
-
$50,000 Jul 19, 2021 Issue: Health Issues
-
$40,000 Apr 16, 2021 Issue: Health Issues
-
$50,000 Jan 15, 2021 Issue: Health Issues
-
$50,000 Oct 20, 2020 Issue: Health Issues
-
$50,000 Jul 17, 2020 Issue: Health Issues
-
$50,000 Apr 16, 2020 Issue: Health Issues
-
$50,000 Jan 17, 2020 Issue: Health Issues
-
$30,000 Oct 21, 2019 Issue: Health Issues
-
$20,000 Jul 22, 2019 Issue: Health Issues
-
$15,000 Jul 09, 2019 Issue: Health Issues
-
$10,000 Apr 19, 2019 Issue: Health Issues
-
$15,000 Apr 12, 2019 Issue: Health Issues
-
$30,000 Jan 19, 2019 Issue: Health Issues
-
$15,000 Jan 17, 2019 Issue: Health Issues
-
$30,000 Oct 22, 2018 Issue: Health Issues
-
$15,000 Oct 03, 2018 Issue: Health Issues
-
$10,000 Jul 31, 2018 Issue: Health Issues
-
$15,000 Jul 09, 2018 Issue: Health Issues
-
$15,000 Apr 12, 2018 Issue: Health Issues
-
$15,000 Jan 08, 2018 Issue: Health Issues
-
$15,000 Oct 19, 2017 Issue: Health Issues
-
$15,000 Jul 06, 2017 Issue: Health Issues
-
$15,000 Apr 05, 2017 Issue: Health Issues
-
$15,000 Jan 11, 2017 Issue: Health Issues
-
$15,000 Oct 24, 2016 Issue: Health Issues
-
$30,000 Jul 11, 2016 Issue: Health Issues
-
$30,000 Apr 19, 2016 Issue: Health Issues
-
$30,000 Jan 13, 2016 Issue: Health Issues
-
$30,000 Oct 22, 2015 Issue: Health Issues
-
$30,000 Jul 13, 2015 Issue: Health Issues
-
$30,000 Apr 20, 2015 Issue: Health Issues
-
$20,000 Jan 14, 2015 Issue: Health Issues
-
$30,000 Oct 18, 2013 Issue: Health Issues
-
$30,000 Jul 22, 2013 Issue: Health Issues
-
$30,000 Apr 22, 2013 Issue: Health Issues
-
$30,000 Jan 18, 2013 Issue: Health Issues
-
$50,000 Oct 22, 2012 Issue: Health Issues
-
$60,000 Jul 20, 2012 Issue: Health Issues
-
$30,000 Apr 16, 2012 Issue: Health Issues
-
$30,000 Jan 16, 2012 Issue: Health Issues
-
$30,000 Oct 17, 2011 Issue: Health Issues
-
$30,000 Jul 14, 2011 Issue: Health Issues
-
$30,000 Apr 18, 2011 Issue: Health Issues
-
$50,000 Jun 09, 2009 Issue: Homeland Security Health Issues
-
$50,000 Jan 17, 2009 Issue: Health Issues Homeland Security
-
$50,000 Oct 17, 2008 Issue: Homeland Security Health Issues
-
$50,000 Jul 19, 2008 Issue: Health Issues Homeland Security
-
$50,000 Apr 21, 2008 Issue: Health Issues Homeland Security
-
$100,000 Feb 14, 2008 Issue: Homeland Security Health Issues
-
$100,000 Aug 04, 2007 Issue: Medical/Disease Research/Clinical Labs
-
$100,000 Feb 14, 2007 Issue: Medical/Disease Research/Clinical Labs
-
$140,000 Aug 08, 2006 Issue: Medical/Disease Research/Clinical Labs
-
$140,000 Feb 07, 2006 Issue: Medical/Disease Research/Clinical Labs
-
$120,000 Aug 15, 2005 Issue: Medical/Disease Research/Clinical Labs
Estimated quarterly lobbying spending
CMRX Revenue by Segment or Geography
New patents grants
-
Patent Title: Pyrrolopyrimidine nucleosides and analogs thereof May. 14, 2024
-
Patent Title: Morphic forms of 4-amino-7-(3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-2-methyl-7h-pyrrolo[2,3-d]pyrimidine-5-carboxamide and uses thereof Sep. 07, 2021
-
Patent Title: Morphic forms of hexadecyloxypropyl-phosphonate esters and methods of synthesis thereof Jul. 20, 2021
-
Patent Title: Pyrrolopyrimidine nucleosides and analogs thereof Mar. 09, 2021
-
Patent Title: Morphic forms of hexadecyloxypropyl-phosphonate esters and methods of synthesis thereof Nov. 26, 2019
-
Patent Title: Pyrrolopyrimidine nucleosides and analogs thereof Sep. 10, 2019
-
Patent Title: Morphic forms of hexadecyloxypropyl-phosphonate esters and methods of synthesis thereof Oct. 30, 2018
-
Patent Title: Methods of treating retroviral infections and related dosage regimes May. 01, 2018
-
Patent Title: Morphic forms of hexadecyloxypropyl-phosphonate esters and methods of synthesis thereof Jan. 09, 2018
-
Patent Title: Nucleoside phosphonate salts Sep. 19, 2017
-
Patent Title: Pyrrolopyrimidine nucleosides and analogs thereof Jul. 18, 2017
-
Patent Title: Pyrrolopyrimidine nucleosides and analogs thereof Jul. 11, 2017
-
Patent Title: Methods of treating retroviral infections and related dosage regimes Jul. 04, 2017
-
Patent Title: Morphic forms of hexadecyloxypropyl-phosphonate esters and methods of synthesis thereof Jun. 21, 2016
-
Patent Title: Phosphonate ester derivatives and methods of synthesis thereof Apr. 05, 2016
-
Patent Title: Methods of treating retroviral infections and related dosage regimes Mar. 08, 2016
-
Patent Title: Nucleoside phosphonate salts Apr. 14, 2015
-
Patent Title: Methods of treating viral infections Mar. 31, 2015
-
Patent Title: Morphic forms of hexadecyloxypropyl-phosphonate esters and methods of synthesis thereof Feb. 24, 2015
-
Patent Title: Compounds, compositions and methods for the treatment of poxvirus infections Feb. 04, 2014
-
Patent Title: Compounds, compositions and methods for treating ocular conditions Dec. 24, 2013
-
Patent Title: Phosphonate ester derivatives and methods of synthesis thereof Oct. 29, 2013
-
Patent Title: Metabolically stable alkoxyalkyl esters of antiviral or antiproliferative phosphonates, nucleoside phosphonates and nucleoside phosphates Aug. 09, 2011
-
Patent Title: Metabolically stable alkoxyalkyl esters of antiviral or antiproliferative phosphonates, nucleoside phosphonates and nucleoside phosphates Jul. 06, 2010
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Recent insights relating to CMRX
Recent picks made for CMRX stock on CNBC
ETFs with the largest estimated holdings in CMRX
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $CMRX stock a Buy, Sell, or Hold?
- What is the price target for $CMRX stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $CMRX stock?
- Who owns the most shares of $CMRX stock?
- What funds own $CMRX stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view CMRX Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.